Press Releases

Date Title and Summary Additional Formats
Toggle Summary Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura
HAYWARD, Calif. , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH) today announced a positive outcome of the pre-specified interim futility analysis for the RESULT Phase 3 clinical study of Sollpura for the treatment of Exocrine Pancreatic Insufficiency (“EPI”).  The
View HTML
Toggle Summary Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal
Delisting notice was expected as part of the compliance extension previously granted by Nasdaq Continue “ANTH” listing until formal hearing process is complete with the Nasdaq Hearings Panel  HAYWARD, Calif. , Nov. 17, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH) announced
View HTML
Toggle Summary Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura
HAYWARD, Calif. , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH) today announced that patient recruitment is now complete for the Phase 3 RESULT clinical study of Sollpura for the treatment of Exocrine Pancreatic Insufficiency (“EPI”) caused by cystic fibrosis.
View HTML
Toggle Summary Anthera Pharmaceuticals Provides Business Update and Reports 2017 Third Quarter Financial Results
RESULT, Phase 3 clinical study of Sollpura, topline data expected Q1 2018 RESULT sanctioned by the European Cystic Fibrosis Society Clinical Trial Network Blisibimod granted FDA orphan drug designation for the treatment of IgA nephropathy Executed a private placement of equity securities for
View HTML
Toggle Summary Anthera Pharmaceuticals Announces Presentation of Blisibimod Data at the American College of Rheumatology Annual Meeting
Presentation will highlight additional analyses of the CHABLIS-SC1, Phase 3 clinical study of blisibimod HAYWARD, Calif. , Nov. 05, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH) will present additional findings from the CHABLIS-SC1, Phase 3 clinical study of blisibimod, a
View HTML
Toggle Summary Anthera Pharmaceuticals Announces Presentations of Sollpura Data at the North American Cystic Fibrosis Conference
HAYWARD, Calif. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH) today announced that data from the SOLUTION, Phase 3 clinical study of Sollpura (liprotamase) and an additional non-clinical study will be presented at the 31 st annual North American Cystic Fibrosis
View HTML
Toggle Summary Anthera Pharmaceuticals Announces Presentation of Blisibimod Lupus Research at the American Society of Nephrology Annual Meeting
Presentation to highlight data from the CHABLIS-SC1, Phase 3 clinical study of blisibimod HAYWARD, Calif. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH) will present new data from the CHABLIS-SC1 Phase 3 clinical study of blisibimod, a novel treatment that targets
View HTML
Toggle Summary Anthera Pharmaceuticals Announces Pricing of $15 Million Private Placement Offering
HAYWARD, Calif. , Oct. 24, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH) today announced that it has entered into a definitive agreement with certain institutional and accredited investors in connection with the private placement of its equity securities (“ PIPE”).
View HTML
Toggle Summary Anthera Pharmaceuticals Surpasses 50% Milestone for Screening of Patients in RESULT Phase 3 Clinical Study of Sollpura in Cystic Fibrosis View HTML
Toggle Summary Anthera Pharmaceuticals to Present at Rodman & Renshaw's 18th Annual Global Investment Conference View HTML